Physician profile
Jonathon M Knox
NPI 1801823505
$20,373.07
in general payments reported to CMS, 2019-2025
59 companies · $3,717 in 2025
The $3,717 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,576 · 2020: $2,094 · 2021: $3,632 · 2022: $2,441 · 2023: $2,338 · 2024: $3,575 · 2025: $3,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,441 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,440.66 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,167.50 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,836.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,834.70 | 2019-2025 | |
| Amgen INC. | $1,561.03 | 2019-2025 | Repatha, Repatha, Evenity |
| Abbvie INC. | $1,501.87 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,089.22 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $1,079.21 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $1,032.88 | 2023-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $888.29 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $779.00 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $676.69 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $575.43 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $475.16 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $436.97 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $391.90 | 2019-2024 | Trintellix |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathon Knox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.